Day: March 18, 2021

WINNIPEG, Manitoba, March 18, 2021 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its fourth quarter and full year 2020 financial results after market close on Thursday, March 25, 2021.Kane Biotech management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.Fourth Quarter and Full Year 2020 Results Conference Call Details: The call will also be broadcast live and archived on the Company’s website at www.kanebiotech.com under “News/Events” in the Investors section.About Kane Biotech Inc.Kane Biotech is a biotechnology company...

NEW YORK, March 18, 2021 (GLOBE NEWSWIRE) — Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multi-national operator and licensed producer of pharmaceutical-grade cannabinoids, will hold a conference call on Tuesday, March 30, 2021 at 5:00 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2020. The Company will provide its financial results in a press release prior to the conference call.Clever Leaves management will host the conference call, followed by a question and answer session.Conference Call Date: March 30, 2021Time: 5:00 p.m. Eastern timeToll-free dial-in number: 1-877-407-9208International dial-in number: 1-201-493-6784Conference ID: 13717604Please call the conference telephone number 5-10 minutes prior to the start time. An operator...

AUSTIN, Texas, March 18, 2021 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the fourth quarter of 2020.“In 2020 and early 2021, we made important progress by advancing our pipeline programs, establishing a new collaboration with a premier oncology partner, and strengthening our balance sheet with a successful equity financing,” said Eric Poma, Ph.D., Molecular Templates’ Chief Executive and Scientific Officer. “We now have four clinical stage programs: MT-5111 targeting HER2, TAK-169 targeting CD38 in co-development with Takeda, MT-6402 with antigen seeding targeting PD-L1, and MT-3724,...

– ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis –– Commercial launch expected in April 2021 –– Kiniksa launches Kiniksa One Connect™ patient support program –– Conference call and webcast scheduled for 5:30 p.m. EDT today –HAMILTON, Bermuda, March 18, 2021 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced the U.S. Food and Drug Administration (FDA) approved ARCALYST ® (rilonacept), a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling, for the treatment of recurrent pericarditis and reduction in...

NEW HAVEN, Conn., March 18, 2021 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2020 and year end corporate update call on Wednesday, March 31st at 5:00 PM ET. The call will include updates on all of the company’s current core businesses.The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10153405/e539a716b4 and will receive a calendar invite and a direct dial-in number, bypassing the operator.Listeners interested in submitting questions in advance should email their questions to investors@precipiodx.com and management will do its best to address those questions during...

SAINT LAURENT, Quebec, March 18, 2021 (GLOBE NEWSWIRE) — IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that it will release its fourth quarter and full-year 2020 financial results after market close on Thursday, March 25, 2021.An accompanying conference call will be hosted by Dr. Horst G. Zerbe, Chief Executive Officer, and Mr. Andre Godin, President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:The call will also be broadcast live and archived on the Company’s website at www.intelgenx.com under “Webcasts” in the Investors section.About IntelGenxIntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.IntelGenx’s superior film technologies,...

MONTREAL, March 18, 2021 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce that the Board of Directors has approved the nomination of Ms. Annie Dutil as Director of the Corporation.“It is a privilege to have Ms. Annie Dutil join our team. Her experience gained while working at Nomad Royalties Company Ltd. (“Nomad”) and PricewaterhouseCoopers (“PwC”) and her knowledge of the capital markets, financing transactions and regulatory and public accounting matters make her an ideal candidate for our Board. We are thrilled to know that the Corporation will benefit from her knowledge and skill set in the years to come”, commented the President and CEO, Mr. Gino Roger.Midland announces that it has granted incentive stock options to Ms. Dutil to acquire 80,000 common shares at $0.88 per share, for a...